Home About
Back to Search

EMEND

FOSAPREPITANT DIMEGLUMINE

Manufacturer: Merck Sharp & Dohme LLC

Score: 141.0

Quick Summary

Fosaprepitant dimeglumine is a substance P/neurokinin-1 (NK1) receptor antagonist used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC). It is administered as an intravenous infusion over 20-30 minutes. The recommended dosage is 150 mg on Day 1, with dexamethasone and a 5-HT3 antagonist. Fosaprepitant is contraindicated in patients with hypersensitivity to any component of the product and in patients taking pimozide. Common adverse reactions include fatigue, diarrhea, neutropenia, asthenia, anemia, and peripheral neuropathy.

Key Clinical Findings and Indications

  • Prevention of acute and delayed nausea and vomiting associated with HEC and MEC
  • Used in combination with other antiemetic agents
  • Administered as an intravenous infusion over 20-30 minutes

Important Safety Information

Warning

Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported

Contraindications

  • Hypersensitivity to any component of the product
  • Concurrent use with pimozide

Adverse Reactions

  • Fatigue
  • Diarrhea
  • Neutropenia
  • Asthenia
  • Anemia
  • Peripheral neuropathy

Dosing Recommendations

General Guidance

No dose adjustments are recommended

HEC

Adult Dose

150 mg on Day 1 as an intravenous infusion over 20-30 minutes

Pediatric Dose

Not established

MEC

Adult Dose

150 mg on Day 1 as an intravenous infusion over 20-30 minutes

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

  • There are insufficient data on use of fosaprepitant in pregnant women to inform a drug-associated risk

Nursing Mothers

  • The efficacy of hormonal contraceptives may be reduced during treatment with fosaprepitant

Pediatric Use

  • The safety and effectiveness of fosaprepitant have not been established in patients less than 6 months of age

Geriatric Use

  • Use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy

Similar Drugs

Fosaprepitant

FOSAPREPITANT

BluePoint Laboratories

Similarity: 94.5%

AKYNZEO

NETUPITANT AND PALONOSETRON

Helsinn Therapeutics (U.S.), Inc.

Similarity: 64.1%

DANYELZA

NAXITAMAB

Y-mAbs Therapeutics, Inc.

Similarity: 61.6%
Back to Search